About the study

HORIZON was a phase 3 clinical trial primarily looking at the effect of dimebon (latrepirdine) on cognitive function in mild-to-moderate Huntington’s disease. It was the first large clinical trial to focus on the cognitive aspects of HD and was a global collaboration between the European Huntington’s Disease Network (EHDN) and Huntington Study Group (HSG), supported by Medivation Inc, and Pfizer Inc.

Latrepirdine (dimebon) is an antihistaminic drug that was first used to treat allergies in the 1980’s. Recently, latrepirdine has been shown to enhance sur­vival of brain cells and improve learning and memory in early phase studies of Alzheimer’s disease (AD) and Huntington’s disease (HD).

The HORIZON trial aimed to compare dimebon 20mg three times daily with placebo (no drug) and was double-blind, so neither investigator or participating subjects knew which treatment arm they were assigned to. The following global regions took part in the HORIZON trial:

• North America (30 sites)
• Australia (3 sites)
• Europe (26 sites; 8 countries)

Unfortunately in April 2011, it was announced that Dimebon had failed to demonstrate improvement in thinking and memory among study participants taking Dimebon 60 mg/day.

http://hdresearch.ucl.ac.uk/all-studies/horizon-dimebon-trial/

For Sale

Dimebon

Dimebom is a new pharmaceutical treatment alternative for patients suffering from Alzheimer’s Disease.   Dimebon is an older medication that has recently been discovered to be most helpful in treating patients with Alzheimer’s disease.   Dimebom (the actual drug is known chemically as Dimebolin) is an older  Russian antihistamine drug.  It was popularly used in Russia as an antihistamine for hayfever, allergies and the like.  In fact the drug was sold as an easy to obtain antihistamine – sold over the counter without a prescription.

Dimebom is currently in clinical trials in the United States by a company named Medivation .    The website for Medivation, the pharmaceutical company involved with the clinical development and testing of Dimebom in the United States? Can be found at link   www.medivation.com .   To learn more about Medivation’s clinical trials of Dimebom the link is

http://www.medivation.com/pipeline_dimebontrials.html#p3

For more information on CONNECTION study locations, eligibility and enrollment, please visit www.connectionstudy.com or call toll-free 1-877-888-6386

At this point in time Dimebom is not available in any manner to Alzheimer Patients or their families, outside of the study material afforded by the Medivation Company and the Medivation clinical trials themselves.

Dimebon Alzheimer?s Disease

http://www.dimebonalzheimers.com

Dimebom is a new pharmaceutical treatment alternative for patients suffering from Alzheimer’s Disease

Dimebon is an older medication that has recently been discovered to be most helpful in treating patients with Alzheimer’s Disease

Dimebon ( the actual drug is known chemically as Dimebolin) is an older Russian antihistamine drug.  It was popularly used in Russia as an antihistamine for hayfever , allergies and the like.  In fact the drug was sold as an easy to obtain antihistamine -  sold over the counter without a prescription.

Dimebon is currently in clinical trials in the United States by a company named  Medivation . The website for Medivation company can be found at http://www.medivation.com/

Dimebon and the clinical trial information of Medivation can be found at this link on the internet

http://www.medivation.com/pipeline_dimebontrials.html

At this point in time Dimebon is not available in any manner outside of the study material afforded by the Medivation company and the Medivation clinical trials themselves.

Dimebon Alzheimer’s Disease

http://www.dimebonalzheimers.com